Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO (brexanolone) Injection for Treatment of Postpartum Depression


#21

Yeah hopefully sage 217 will be the price of normal SSRI’s or near enough to that, something everyone can easily get their hands on.


#22

Indeed. The significant cost upfront for Brexanolone is that it has to be administered by a qualifying nurse for 60 hours straight in a hospital setting.

Further, if you’re employed, it’ll be very likely that you will have complete or partial coverage :).